Enanta Pharma (NASDAQ: ENTA) reported quarterly losses of $(0.67) per share which missed the analyst consensus estimate of $(0.54) by 26.42 percent. This is a 21.18 percent increase over losses of $(0.85) per share from the same period last year. The company reported quarterly sales of $14.359 million which missed the analyst consensus estimate of $16.796 million by 14.51 percent. This is a 21.60 percent decrease over sales of $18.314 million the same period last year.